USFDA Approves Zydus’ OCD Treatment Drug
A wholly owned subsidiary of Cadila Healthcare Limited, Zydus Pharmaceuticals has now received approval from the US FDA to market clomipramine hydrochloride capsules. Clomipramine hydrochloride capsule is used to treat obsessive compulsive disorder, which is characterised by uncontrollable, re-occurring thoughts and behaviours.
The company has received final approval from the US Food and Drug Administration (USFDA) to market the drug in 25 mg, 50 mg and 75 mg strengths.
The company will produce the drug at the group’s formulations manufacturing facility at SEZ, Ahmedabad.